JP2009535298A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535298A5
JP2009535298A5 JP2009502932A JP2009502932A JP2009535298A5 JP 2009535298 A5 JP2009535298 A5 JP 2009535298A5 JP 2009502932 A JP2009502932 A JP 2009502932A JP 2009502932 A JP2009502932 A JP 2009502932A JP 2009535298 A5 JP2009535298 A5 JP 2009535298A5
Authority
JP
Japan
Prior art keywords
cell
cancer
anticancer agent
cancer cells
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP5422377B2 (ja
JP2009535298A (ja
Filing date
Publication date
Priority claimed from US11/389,695 external-priority patent/US9107863B2/en
Application filed filed Critical
Publication of JP2009535298A publication Critical patent/JP2009535298A/ja
Publication of JP2009535298A5 publication Critical patent/JP2009535298A5/ja
Application granted granted Critical
Publication of JP5422377B2 publication Critical patent/JP5422377B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009502932A 2006-03-27 2007-03-27 癌の処置および予防のための試薬および方法 Expired - Fee Related JP5422377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/389,695 US9107863B2 (en) 2006-03-27 2006-03-27 Reagents and methods for cancer treatment and prevention
US11/389,695 2006-03-27
PCT/US2007/007526 WO2007126787A2 (en) 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013170115A Division JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Publications (3)

Publication Number Publication Date
JP2009535298A JP2009535298A (ja) 2009-10-01
JP2009535298A5 true JP2009535298A5 (https=) 2011-05-12
JP5422377B2 JP5422377B2 (ja) 2014-02-19

Family

ID=38533710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009502932A Expired - Fee Related JP5422377B2 (ja) 2006-03-27 2007-03-27 癌の処置および予防のための試薬および方法
JP2013170115A Expired - Fee Related JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013170115A Expired - Fee Related JP5712257B2 (ja) 2006-03-27 2013-08-20 癌の処置および予防のための試薬および方法

Country Status (8)

Country Link
US (4) US9107863B2 (https=)
EP (2) EP2974738B1 (https=)
JP (2) JP5422377B2 (https=)
CN (1) CN101443036A (https=)
AU (1) AU2007245169B2 (https=)
CA (1) CA2647542A1 (https=)
ES (2) ES2548435T3 (https=)
WO (1) WO2007126787A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376495B2 (ja) 1992-08-18 2003-02-10 ソニー株式会社 接着剤の塗布方法及び接着治具
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
CZ300806B6 (cs) * 2007-07-18 2009-08-12 Ústav experimentální mediciny AV CR, v.v.i. Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy
CA2903599A1 (en) * 2013-03-15 2014-09-18 Genspera, Inc. Methods for making cancer compositions
EP2796137A1 (en) * 2013-04-22 2014-10-29 Universität des Saarlandes SERCA inhibitor and Calmodulin antagonist combination
CN112891354B (zh) * 2021-03-18 2022-10-21 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
IN165717B (https=) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
WO2000072686A1 (en) 1999-06-02 2000-12-07 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
JP2001010973A (ja) * 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
EP1441034A4 (en) * 2001-10-31 2006-06-07 Astellas Pharma Inc METHOD FOR EVALUATING PHOSPHATASE INHIBITORS
WO2003087129A2 (en) * 2002-04-08 2003-10-23 Siga Technologies, Inc. Immunogenic peptides, and method of identifying same
EP1578459A3 (en) 2002-10-25 2005-11-23 University of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
ES2469670T3 (es) * 2003-11-30 2014-06-18 Yeda Research And Development Co., Ltd. Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention

Similar Documents

Publication Publication Date Title
JP7055906B2 (ja) 細胞膜透過性を増加させるための交流電界の使用
Sultan et al. Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial
US20190099398A1 (en) Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
Jiang et al. Preparation and anti-tumor metastasis of carboxymethyl chitosan
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
GB0223380D0 (en) Combination therapy
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
DE60331933D1 (de) Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
MX383644B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
JP2009535298A5 (https=)
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
IL191796A0 (en) Combination of zd6474 and pemetrexed
Farooqi Regulation of deregulated cell signaling pathways by pomegranate in different cancers: Re-interpretation of knowledge gaps
ATE418965T1 (de) Medikamentöse gezielte lokale lipolyse
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
Xu et al. Endothelial Foxo1 Phosphorylation Inhibition via Aptamer‐Liposome Alleviates OPN‐Induced Pathological Vascular Remodeling Following Spinal Cord Injury
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
ATE502641T1 (de) Kombination aus azd2171 und pemetrexed
IL177953A0 (en) Combination therapy including azd2171 and a taxane
GB0406446D0 (en) Combination therapy
IL172682A0 (en) Combination therapy
BRPI0508959A (pt) uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente